FDA Approves Sunlenca For Treatment-Resistant HIV Patients
With the recent FDA approval of Sunlenca, treatment-resistant HIV patients have a new medication option. This new medication works by disrupting the cone-shaped shell that surrounds the virus’ genetic material. It must be used in combination with other antiretroviral drugs.
SUNLENCA works by disrupting the cone-shaped shell surrounding the HIV-1 virus’ genetic material
The first in a new class of drugs, Sunlenca (lenacapavir) is a long-acting antiviral that works by blocking the HIV-1 virus’ protein shell. It has been tested in clinical trials in patients with high viral loads in the blood. In addition, it has been approved in the United States and the European Union for the treatment of adults with multidrug-resistant HIV infection.
Despite the high prevalence of HIV in the global population, most infected individuals are not able to access advanced therapy options. This has led to a race against drug resistance. By developing innovative antiviral strategies, researchers hope to win this battle.
One important area of research has been structural biology. Structural studies have provided insights into drug targets. For instance, the structures of the HIV-1 protein capsid have been the target of numerous antiretrovirals. However, there was limited understanding of the mechanisms that govern interaction between the virus and the host.
Recent NMR studies have provided insight into the structure of the lipid membrane-embedded TM peptides. These peptides likely contain an antiparallel helix-helix binding interface.
SUNLENCA must be used in combination with other antiretroviral drugs
Sunlenca is a new drug for people with HIV who have developed resistance to other drugs. It is a long-acting antiretroviral that is given twice a year. However, this type of treatment can have a lot of negative side effects. The most common are injection site reactions. Other problems include induration, swelling, and pain.
While most antiretrovirals act on one stage of the virus’s life cycle, Sunlenca disrupts the cone-shaped shell of the HIV virus. This may help stop it from spreading from person to person.
The drug is available as a tablet, injection, or infusion. It is the first of a new class of drugs called capsid inhibitors. In fact, the FDA has granted lenacapavir with Breakthrough Therapy Designation, which means that it is a fast-track to approval.
It is given as a maintenance injection every six months. If it is used in conjunction with other antiretrovirals, it can be a good option for patients with treatment-resistant HIV.
SUNLENCA has a long-acting PrEP option
Sunlenca is an antiretroviral drug that is used to treat HIV. It works by inhibiting multiple stages of viral replication. The active substance in Sunlenca is lenacapavir, which binds to proteins on the outer layer of the HIV-1 virus. This allows the HIV to be reduced to a low level.
It is approved in the United States, Canada, and the European Union. In the United States, Sunlenca is indicated for adult patients with HIV infection who have not been adequately treated with other available treatments.
For those who have had treatment with other HIV medications, Sunlenca can be given in tablet form. It can also be given as a subcutaneous injection. These types of injections are easier to administer than oral pills. However, people may experience problems with the injection site, such as persistent nodules.
Another long-acting PrEP option is ViiV Healthcare’s Cabenuva, which contains injectable cabotegravir. This can be administered once or twice a month.
According to Gilead Sciences, which is developing Sunlenca, it is designed to work differently than existing drugs. It is also believed to be effective in treating individuals with HIV that has developed resistance to previous drugs.
SUNLENCA is a biopharmaceutical company
The biopharmaceutical company Gilead Sciences has received marketing authorization from the European Commission for its HIV drug Sunlenca. It is the first of a new class of antiviral drugs, called capsid inhibitors. These drugs interfere with multiple stages of the virus’ life cycle.
Gilead developed Sunlenca (lenacapavir) for treating treatment-resistant HIV. It works by binding to proteins on the outer surface of the virus. This interferes with multiple steps in the virus’ replication process. By doing this, it allows the immune system to heal itself.
Sunlenca is administered in combination with other antiretroviral drugs. The drug is available as both a tablet and an injection. When the drug is injected, it is followed by maintenance therapy, which involves injections every six months.
Sunlenca is a drug that was studied in a multicenter clinical trial. In the trial, it was given to 72 patients who were resistant to several HIV medications. Eighty-three percent of them achieved undetectable viral loads after one year of therapy.
